Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2407 | 2255 | 40.3 | 80% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
5 | 4 | CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY | 1745167 |
183 | 3 | APTAMER//G QUADRUPLEX//RIBOZYME | 56307 |
389 | 2 | NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS//OLIGONUCLEOTIDES//PEPTIDE NUCLEIC ACID | 16949 |
2407 | 1 | ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT//ANTISENSE OLIGONUCLEOTIDES//ANTISENSE RESEARCH AND DEVELOPMENT | 2255 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | journal | 586867 | 6% | 34% | 127 |
2 | ANTISENSE OLIGONUCLEOTIDES | authKW | 388163 | 9% | 13% | 213 |
3 | ANTISENSE RESEARCH AND DEVELOPMENT | journal | 309437 | 2% | 57% | 40 |
4 | ANTISENSE | authKW | 295248 | 10% | 10% | 215 |
5 | PHOSPHOROTHIOATE | authKW | 250368 | 3% | 25% | 74 |
6 | OLIGONUCLEOTIDES | authKW | 223059 | 9% | 8% | 213 |
7 | OLIGODEOXYNUCLEOTIDE | authKW | 109416 | 2% | 15% | 55 |
8 | PHOSPHOROTHIOATE OLIGONUCLEOTIDES | authKW | 101174 | 1% | 36% | 21 |
9 | ANTISENSE OLIGODEOXYNUCLEOTIDE | authKW | 97189 | 2% | 13% | 55 |
10 | C 5 PROPYNE | authKW | 54158 | 0% | 100% | 4 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Biochemistry & Molecular Biology | 5999 | 44% | 0% | 988 |
2 | Medicine, Research & Experimental | 2453 | 13% | 0% | 298 |
3 | Pharmacology & Pharmacy | 2318 | 21% | 0% | 464 |
4 | Biotechnology & Applied Microbiology | 2136 | 14% | 0% | 320 |
5 | Chemistry, Medicinal | 479 | 5% | 0% | 114 |
6 | Biochemical Research Methods | 468 | 6% | 0% | 129 |
7 | Oncology | 455 | 9% | 0% | 212 |
8 | Biophysics | 233 | 5% | 0% | 108 |
9 | Virology | 225 | 3% | 0% | 66 |
10 | Hematology | 105 | 3% | 0% | 66 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ASTON GENE BASED THER EUT | 27079 | 0% | 100% | 2 |
2 | JIANGXI OAI GEMEINSAMES | 27079 | 0% | 100% | 2 |
3 | PSYCHIAT 6214 | 27079 | 0% | 100% | 2 |
4 | STELLAR CHANCE S 513B | 27079 | 0% | 100% | 2 |
5 | CHEM G 838 | 27075 | 0% | 50% | 4 |
6 | BIOTECHNOL BASED MED | 18051 | 0% | 67% | 2 |
7 | CHIM THER EUT RADIOPHARM | 18051 | 0% | 67% | 2 |
8 | GRP DRUG TARGETING DELIVERY POORLY STABLE CPDS | 18051 | 0% | 67% | 2 |
9 | IFR PATHOL INFECT INSERM U386 | 18051 | 0% | 67% | 2 |
10 | UCL 7541 | 18051 | 0% | 67% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | 586867 | 6% | 34% | 127 |
2 | ANTISENSE RESEARCH AND DEVELOPMENT | 309437 | 2% | 57% | 40 |
3 | NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 25012 | 4% | 2% | 93 |
4 | NUCLEIC ACID THERAPEUTICS | 13616 | 1% | 6% | 16 |
5 | ANTI-CANCER DRUG DESIGN | 13448 | 1% | 4% | 25 |
6 | OLIGONUCLEOTIDES | 12855 | 1% | 6% | 16 |
7 | CURRENT OPINION IN MOLECULAR THERAPEUTICS | 11254 | 1% | 3% | 27 |
8 | NUCLEIC ACIDS RESEARCH | 8704 | 7% | 0% | 161 |
9 | ANTIVIRAL RESEARCH | 1853 | 1% | 1% | 22 |
10 | JOURNAL OF DRUG TARGETING | 1681 | 1% | 1% | 14 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ANTISENSE OLIGONUCLEOTIDES | 388163 | 9% | 13% | 213 | Search ANTISENSE+OLIGONUCLEOTIDES | Search ANTISENSE+OLIGONUCLEOTIDES |
2 | ANTISENSE | 295248 | 10% | 10% | 215 | Search ANTISENSE | Search ANTISENSE |
3 | PHOSPHOROTHIOATE | 250368 | 3% | 25% | 74 | Search PHOSPHOROTHIOATE | Search PHOSPHOROTHIOATE |
4 | OLIGONUCLEOTIDES | 223059 | 9% | 8% | 213 | Search OLIGONUCLEOTIDES | Search OLIGONUCLEOTIDES |
5 | OLIGODEOXYNUCLEOTIDE | 109416 | 2% | 15% | 55 | Search OLIGODEOXYNUCLEOTIDE | Search OLIGODEOXYNUCLEOTIDE |
6 | PHOSPHOROTHIOATE OLIGONUCLEOTIDES | 101174 | 1% | 36% | 21 | Search PHOSPHOROTHIOATE+OLIGONUCLEOTIDES | Search PHOSPHOROTHIOATE+OLIGONUCLEOTIDES |
7 | ANTISENSE OLIGODEOXYNUCLEOTIDE | 97189 | 2% | 13% | 55 | Search ANTISENSE+OLIGODEOXYNUCLEOTIDE | Search ANTISENSE+OLIGODEOXYNUCLEOTIDE |
8 | C 5 PROPYNE | 54158 | 0% | 100% | 4 | Search C+5+PROPYNE | Search C+5+PROPYNE |
9 | PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES | 44305 | 0% | 55% | 6 | Search PHOSPHOROTHIOATE+OLIGODEOXYNUCLEOTIDES | Search PHOSPHOROTHIOATE+OLIGODEOXYNUCLEOTIDES |
10 | RNASE H | 43996 | 1% | 12% | 28 | Search RNASE+H | Search RNASE+H |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | CROOKE, ST , (2004) PROGRESS IN ANTISENSE TECHNOLOGY.ANNUAL REVIEW OF MEDICINE. VOL. 55. ISSUE . P. 61-95 | 85 | 68% | 297 |
2 | GARCIA-CHAUMONT, C , SEKSEK, O , GRZYBOWSKA, J , BOROWSKI, E , BOLARD, J , (2000) DELIVERY SYSTEMS FOR ANTISENSE OLIGONUCLEOTIDES.PHARMACOLOGY & THERAPEUTICS. VOL. 87. ISSUE 2-3. P. 255 -277 | 120 | 65% | 76 |
3 | CROOKE, ST , (2000) PROGRESS IN ANTISENSE TECHNOLOGY: THE END OF THE BEGINNING.ANTISENSE TECHNOLOGY, PT A. VOL. 313. ISSUE . P. 3 -45 | 97 | 67% | 121 |
4 | DIAS, N , STEIN, CA , (2002) ANTISENSE OLIGONUCLEOTIDES: BASIC CONCEPTS AND MECHANISMS.MOLECULAR CANCER THERAPEUTICS. VOL. 1. ISSUE 5. P. 347-355 | 66 | 59% | 353 |
5 | CROOKE, ST , (2004) ANTISENSE STRATEGIES.CURRENT MOLECULAR MEDICINE. VOL. 4. ISSUE 5. P. 465 -487 | 73 | 61% | 93 |
6 | STEIN, CA , CHENG, YC , (1993) ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS - IS THE BULLET REALLY MAGICAL.SCIENCE. VOL. 261. ISSUE 5124. P. 1004-1012 | 62 | 51% | 1235 |
7 | LEBEDEVA, IV , STEIN, CA , (2000) ANTISENSE OLIGONUCLEOTIDES IN CANCER - RECENT ADVANCES.BIODRUGS. VOL. 13. ISSUE 3. P. 195 -216 | 106 | 51% | 11 |
8 | CROOKE, ST , BENNETT, CF , (1996) PROGRESS IN ANTISENSE OLIGONUCLEOTIDE THERAPEUTIC.ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. VOL. 36. ISSUE . P. 107-129 | 83 | 55% | 239 |
9 | CROOKE, ST , (1998) ANTISENSE THERAPEUTICS.BIOTECHNOLOGY & GENETIC ENGINEERING REVIEWS, VOL. 15. VOL. 15. ISSUE . P. 121 -157 | 92 | 57% | 53 |
10 | GEWIRTZ, AM , SOKOL, DL , RATAJCZAK, MZ , (1998) NUCLEIC ACID THERAPEUTICS: STATE OF THE ART AND FUTURE PROSPECTS.BLOOD. VOL. 92. ISSUE 3. P. 712 -736 | 99 | 44% | 187 |
Classes with closest relation at Level 1 |